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Abstract
Background: Pneumococcal epidemiology varies geographically and few data are available from the African continent. We
assess pneumococcal carriage from studies conducted in sub-Saharan Africa (sSA) before and after the pneumococcal
conjugate vaccine (PCV) era.
Methods: A search for pneumococcal carriage studies published before 2012 was conducted to describe carriage in sSA.
The review also describes pneumococcal serotypes and assesses the impact of vaccination on carriage in this region.
Results: Fifty-seven studies were included in this review with the majority (40.3%) from South Africa. There was considerable
variability in the prevalence of carriage between studies (I-squared statistic = 99%). Carriage was higher in children and
decreased with increasing age, 63.2% (95% CI: 55.6–70.8) in children less than 5 years, 42.6% (95% CI: 29.9–55.4) in children
5–15 years and 28.0% (95% CI: 19.0–37.0) in adults older than 15 years. There was no difference in the prevalence of carriage
between males and females in 9/11 studies. Serotypes 19F, 6B, 6A, 14 and 23F were the five most common isolates. A meta-
analysis of four randomized trials of PCV vaccination in children aged 9–24 months showed that carriage of vaccine type
(VT) serotypes decreased with PCV vaccination; however, overall carriage remained the same because of a concomitant
increase in non-vaccine type (NVT) serotypes.
Conclusion: Pneumococcal carriage is generally high in the African continent, particularly in young children. The five most
common serotypes in sSA are among the top seven serotypes that cause invasive pneumococcal disease in children
globally. These serotypes are covered by the two PCVs recommended for routine childhood immunization by the WHO. The
distribution of serotypes found in the nasopharynx is altered by PCV vaccination.
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Introduction
The human nasopharynx is the main reservoir for pneumococ-
ci. The bacteria which adhere to pharyngeal epithelial cells
through epithelial receptor molecules may be acquired very early
in life [1,2], and in most children the pneumococcus is present in
the nasopharynx at some point in the first few years of life [3].
Carriage is generally higher in developing countries and among
economically deprived populations [4,5]. The prevalence of
carriage might also vary between developing countries. In one
study, Abdullahi et al suggested that colonisation prevalence in
East and Southern Africa is substantially lower than in the Gambia
[6]. High prevalence have however been reported in Ethiopia and
Mozambique.
Carriage is a prerequisite for disease [3,7] and because it is
much more common than a disease outcome, it may be a valuable
measure of the efficacy of new pneumococcal vaccines [8]. The
relation between carriage and disease was first demonstrated in a
cohort of infants [9]. Subsequent studies showed that carriage is a
risk factor for acute and recurrent otitis media in children [10,11].
Other studies have shown that bacterial carriage densities may be
related to the risk of disease in adults and children [12,13], and
O’Brien et al have suggested that PCV may reduce carriage
density in children [14].
Since the introduction of PCV, several studies have reported a
reduction in invasive pneumococcal disease (IPD). However, this is
frequently accompanied by a change in the distribution of
circulating serotypes. A decrease in vaccine type (VT) IPD and
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an increase in non-vaccine type (NVT) IPD have been reported in
America [15], Spain [16], Canada [17] and Australia [18]. In
particular, serotype 19A has been isolated more frequently after
the introduction of PCV 7 [19–22].
This review of pneumococcal carriage in sSA aims to: 1)
describe the variability in carriage prevalence across countries in
sSA; 2) describe the distribution of serotypes, and 3) assess the
impact of pneumococcal vaccination on carriage of VT and NVT
serotypes.
Methods
A comprehensive literature search strategy was developed to
identify published articles describing pneumococcal carriage in
sSA (Appendix S1). The search was conducted in December 2011
using the electronic databases MEDLINE (from 1950), EMBASE
(from 1947) and African Index Medicus (AIM). To ensure the
retrieval of relevant articles, the search was performed by
exploring and combining medical subject headings (MeSH) and
free search terms relating to carriage, nasopharyngeal, oropha-
Figure 1. Flow chart for eligible articles.
doi:10.1371/journal.pone.0085001.g001
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Table 1. Characteristics of studies included in the review (n = 32,253).
First author,(ref) Country Year Age Population Swab type Route Swabs/person
Central Africa
Rowe, [47] CAR 1995 2 m–58 m opda c.alginate NPS single
Ndip, [48] Cameron 2004 10 y–21 y schoolb ns OPS single
East Africa
Ringertz, [49] Ethiopia 1987 ,5 y comm c.alginate NPS single
Rusen, [50] Kenya 1990 ,5 y opdc c.alginate NPS single
Joloba, [51] Uganda 1995 ,3 y opdd c.alginate NPS single
Batt, [52] Tanzania 2000 ,7 y comm cotton OPS single
Scott, [53] Kenya 2000 ,7 y comm/hosp dacron NPS single
Nyandiko, [54] Kenya 2003 ,42 m opde dacron NPS single
Abdullahi, [6] Kenya 2004 all comm rayon NPS twice
Blossom, [55] Uganda 2004 20 y–55 y HIV BBL OPS single
Abdullahi, [56] Kenya 2006 ,5 y opdf rayon NPS single/multipleg
Haug, [57] Ethiopia 2003/6 1 y–5 y comm ns NPS single
Skalet, [58] Ethiopia 2006 ,10 y comm ns NPS single
Scott, [27] Kenya 2004/7 ,1 y EPI rayon NPS single
Southern Africa
Jacobs, [59] South Africa 1977 all hosph c.alginate NPS single
Klugman, [60] South Africa 1977 ,5 yi DCC c.alginate NPS single
Robins-Browne, [61] South Africa 1981 ,12 y hosp c.alginate NPS single
Oppenheim, [62] South Africa 1983 ,10 y hosp c.alginate NPS multiple
Frederiksen, [63] Zambia 1986 ,10 y opdd cotton OPS single
Woolfson, [64] Zambia 1994 ,6 y opda c.alginate NPS single
Mthwalo, [65] Lesotho 1995 ,5 y comm c.alginate NPS single
Yomo, [66] Malawi 1995 ,5 y MCH cotton both multiple
Feikin, [67] Malawi 1997 2 w–59 m opdf ns NPS single
Feikin, [68] Malawi 1997 2 w–59 m opda ns NPS multiple
Huebner, [69] Botswana 1997 2 m–5 y opd/ward c.alginate NPS single
Gordon, [70] Malawi 1998 all ns cotton NPS single
McNally, [36] South Africa 2001 1 m–59 m hospj wire NPS single
Cotton, [71] South Africa 2002 8 w–5 y HIV wire NPS single
Pemba, [45] South Africa 2002 adults HIV c.alginate Both twice
Gill, [45] Zambia 2003 6 w–18 m HIV+ve/2ve c.alginate NPS single/multipleg
Valles, [72] Mozambique 2003 ,5 y opd c.alginate NPS Single
von Gottberg, [73] South Africa 2006 all hospk dacron NPS single
Mbelle, [28] South Africa 1999l ,1 y comm c.alginate NPS multiple
Huebner, [74] South Africa 2000l 2 m–5 y clinicd c.alginate NPS single
Mwenya, [75] Zambia 2002 6 m–14 y HIV rayon NPS single
Marcus, [76] South Africa 1993 3 m–8 y school c.alginate NPS single
West Africa
Hansman, [77] Nigeria 1977 ns opda ns NPS single
Lloyd- Evans, [78] Gambia 1989 all comm/hosp cotton NPS single/multipleg
Obaro, [30] Gambia 1995 2 y comm ns NPS single
Denno, [79] Ghana 1996 ,1 y opde wire NPS single
Kacou-Ndouba, [80] Ivory Coast 1997 ,5 y EPI c.alginate NPS single
Obaro, [25] Gambia 2000 ,1 y EPI cotton NPS twice
Darboe, [81] Gambia 2001 all comm c.alginate NPS multiple
Adegbola, [82] Gambia 2001l 3–4 y comm c.alginate NPS single
Hill, [83] Gambia 2003/4 all comm c.alginate NPS single
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ryngeal, Streptococcus pneumoniae, serotypes, pneumococcal vaccine
and specific names of the African countries. Titles and abstracts
were reviewed and duplicates, non-relevant studies, and those
involving streptococcal infections other than S. pneumoniae were
excluded (Figure 1). The full texts of potential papers were then
screened for eligibility.
Inclusion and exclusion criteria
The review was limited to studies from countries within the sSA
region that reported the prevalence of carriage with or without
serotyping of the pneumococcal isolates. We used data from both
hospital and community based studies that collected swabs from
either the nasopharynx or oropharynx. The search was limited to
human subjects but there was no restriction on the age of
participants, study design or language of publication. Bibliogra-
phies of relevant papers and review papers were searched to
identify articles that may have been missed in the electronic
search.
Data analysis
Data were obtained for the following variables: prevalence of S.
pneumoniae, country, first author, year the study was conducted (or
year of publication if the study year was not reported), age of
participants, number of swabs collected per individual, health of
the population swabbed, rural or urban setting, and season or
months of the year when the study was conducted. The data were
entered in an Excel spread sheet and Stata version 12 was used for
all analyses. For studies with multiple swabs per individual, only
results from the first swab were included in the analysis and for
those with interventions, either PCV or other interventions such as
antibiotics, only the control arm was included in the analysis. To
assess the impact of PCV we used data from randomised trials
where PCV was the intervention. The extracted data were
reviewed independently by a second reviewer who checked the
data to ensure completeness using the template prepared for data
extraction.
To describe the prevalence of carriage by age, the studies were
grouped as: ,5 years (children), 5–15 years (children), and .15
years (adults). Studies that recruited children in both age groups
were assigned to the age group 5–15 years. Studies where
participants were recruited across child and adult age groups, and
where suitable stratified results were unavailable were excluded
from the analysis of carriage by age. A random-effects model was
used to summarise carriage by age group across the different
studies. Studies where the standard error of the prevalence could
not be computed were excluded from this analysis. The effects of
region, season and urban/rural location on carriage were
examined by comparing between studies using random effects
model (meta-regression). For each study that reported carriage by
gender, the absolute difference in prevalence between males and
females (risk difference) was calculated and statistical significance
was determined using Fisher’s exact test.
Table 1. Cont.
First author,(ref) Country Year Age Population Swab type Route Swabs/person
Hill, [2] Gambia 2008l ,1 y comm c.alginate NPS multiple
Nwachukwu, [37] Nigeria 2008l 2 m–59 m EPI ns NPS single
Bere, [84] Burkina Faso 2000 ,5 y MCH c.alginate NPS single
Cheung, [29] Gambia 2003 9 m–27 m comm ns NPS multiple
Kandakai-Olukemi, [85] Nigeria 2009l 15 y–25 y school cotton NPS single
Mureithi, [86] Gambia 2009l 19 y–50 y comm ns NPS single
Darboe, [1] Gambia 2010l ,1 y clinic c.alginate NPS multiple
Donkor, [87] Ghana 2006 ,13 y hospm ns NPS single
Hill, [88] Gambia 2010l All comm ns NPS multiple
Kacou-N’douba, [89] Ivory Coast 2010l ,5 y ns ns ns single
Ota, [26] Gambia 2011l ,1 y EPI c.alginate NPS single
Roca, [24] Gambia 2006/8 All ages comm c.alginate NPS single
Ref- reference, N-number of individuals, ns- not stated; NPS- Nasopharyngeal swab; OPS- Oropharyngeal swab; c.alginate- Calcium Alginate; w-week, m-months, y-years,
comm- community, opd-outpatient department, hosp-hospital, EPI -Expanded programme on immunisation clinic, DCC- day care centre, MCH- mother & child clinic,
aany illness,
bwith respiratory tract infection,
cperinatal follow up HIV clinic used control group,
droutine check or immunisation,
emedical conditions as well as routine checks,
fminor illnesses no hospitalisations,
gsome swabbed once others swabbed more than once,
hchildren and carers sick and well,
Iadults also swabbed age not specified,
jhosp severe pneumonia,
ktuberculosis patients,
lyear published,
mpatients returning for review after minor illness.
doi:10.1371/journal.pone.0085001.t001
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Table 2. Pneumococcal carriage prevalence in sub Saharan Africa by age.
A
First author, year Country Prevalence 95% CI % Wt
Hansman, 1977 Nigeria 44.4 34.6 54.2 2.50
Jacobs, 1977 South Africa 41.8 37.6 45.9 2.58
Klugman, 1977 South Africa 58.2 54.6 61.8 2.59
Ringertz, 1987 Ethiopia 89.8 88.0 91.6 2.60
Lloyd- Evans, 1989 Gambia 85.1 83.0 87.2 2.60
Rusen, 1990 Kenya 22.5 13.5 31.6 2.51
Woolfson, 1994 Zambia 71.9 66.4 77.4 2.57
Mthwalo, 1995 Lesotho 59.6 55.4 63.8 2.58
Yomo, 1995 Malawi 47.5 40.6 54.4 2.55
Rowe, 1995 CAR 71.2 66.8 75.6 2.58
Joloba, 1995 Uganda 61.8 54.9 68.7 2.55
Obaro, 1995 Gambia 93.8 90.1 97.5 2.59
Denno, 1996 Ghana 51.4 45.8 57.0 2.57
Kacou-Ndouba, 1997 Ivory Coast 63.3 56.9 69.7 2.56
Feikin, 1997 Malawi 87.0 84.8 89.2 2.59
Huebner, 1997 Botswana 69.1 63.6 74.5 2.57
Feikin, 1997 Malawi 84.0 81.6 86.4 2.59
Gordon, 1998 Malawi 42.0 35.4 48.1 2.56
Mbelle, 1999 South Africa 61.0 54.8 67.2 2.56
Huebner, 2000 South Africa 39.9 34.4 45.4 2.57
Obaro, 2000 Gambia 92.1 88.4 95.8 2.59
Bere, 2000 Burkina Faso 50.7 47.4 54.0 2.59
Adegbola, 2001 Gambia 87.0 80.5 93.5 2.55
McNally, 2001 South Africa 47.6 42.4 52.8 2.57
Darboe, 2001 Gambia 81.0 73.2 88.3 2.53
Cotton, 2002 South Africa 22.2 16.5 27.9 2.56
Hill, 2003 Gambia 93.4 88.7 98.1 2.58
Cheung, 2003 Gambia 86.1 84.0 88.2 2.60
Gill, 2003 Zambia 25.8 23.6 28.1 2.59
Nyandiko, 2003 Kenya 35.9 25.2 46.5 2.48
Valles, 2003 Mozambique 87.0 83.1 90.9 2.58
Haug, 2003 Ethiopia 93.3 88.8 97.8 2.58
Scott, 2004 Kenya 78.0 73.0 83.0 2.57
Abdullahi, 2004 Kenya 57.0 52.4 61.6 2.58
Abdullahi, 2006 Kenya 76.0 65.4 86.6 2.48
Hill, 2008 Gambia 86.0 81.6 90.4 2.58
Nwachukwu, 2008 Nigeria 69.0 58.2 79.8 2.47
Kacou-N’douba, 2010 Ivory Coast 27.5 24.7 30.3 2.59
Darboe, 2010 Gambia 21.0 15.3 26.7 2.56
Overall prevalence 63.2 55.6 70.8 100.00
I2(%), p-value 99.33, ,0.001
B
First author, year Country Prevalence 95% CI % Wt
Robins-Browne, 1981 South Africa 31.0 27.2 34.8 7.80
Oppenheim, 1983 South Africa 24.5 23.0 25.9 7.85
Frederiksen, 1986 Zambia 16.0 11.4 20.6 7.78
Lloyd- Evans, 1989 Gambia 63.0 56.9 69.1 7.72
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Data from four of the studies were pooled to assess the impact of
PCV on overall carriage and the carriage of VT and NVT
serotypes among children 9 to 24 months. In all four studies
children who received no PCV were compared with children who
received at least three doses of PCV. Random effects models were
used to estimate the average effect of PCV (DerSimonian-Laird
estimate) across studies and to assess the degree of heterogeneity
between studies.
Serotypes isolated in each study were ranked in order of
prevalence and the five most prevalent serotypes in each study
were identified. For each serotype, we determined the proportion
of studies in which it was among five most prevalent serotypes.
Quality of the studies
The studies were reviewed for quality using the WHO
guidelines for conducting nasopharyngeal studies. The guidelines
are for the material used for sample collection, the technique of
sample collection, and the transport media [23]. For each study,
we identified potential sources of bias in the method of selection of
study subjects.
Results
Characteristics of the studies
A total of 57 studies were included in this review (Table 1).
Southern Africa contributed the most studies, 23(40.3%). Twenty
studies (35.1%) were fromWest Africa with more than half of these
from The Gambia. There were 12(21.1%) and 2(3.5%) studies
from East and Central Africa respectively.
The majority of the studies (87.7%) collected nasopharyngeal
swabs, only 4(7.0%) collected oropharyngeal swabs, and 2(3.5%)
studies collected both. In one study, the anatomical site of
sampling was not reported. Calcium alginate was the most
Table 2. Cont.
B
First author, year Country Prevalence 95% CI % Wt
Marcus, 1993 South Africa 40.6 31.2 49.9 7.54
Scott, 2000 Kenya 37.0 30.2 43.8 7.88
Batt, 2000 Tanzania 10.7 9.0 12.4 7.85
Mwenya, 2002 Zambia 55.0 44.7 65.3 7.47
Hill, 2003 Gambia 86.3 82.5 90.1 7.80
Abdullahi, 2004 Kenya 41.0 36.3 45.7 7.77
Skalet, 2006 Ethiopia 81.7 74.8 88.6 7.68
Donkor, 2006 Ghana 15.3 9.0 21.6 7.71
von Gottberg, 2007 South Africa 53.8 41.7 65.9 7.34
Overall prevalence 42.6 29.9 55.4 100.00
I2(%), pvalue 99.34, , 0.001
C
First author, year Country Prevalence 95% CI % Wt
Klugman, 1977 South Africa 15.4 8.2 22.5 7.75
Jacobs, 1977 South Africa 9.9 7.1 12.7 8.08
Lloyd- Evans, 1989 Gambia 20.0 20.9 40.9 5.65
Gordon, 1998 Malawi 10.8 8.1 13.5 8.08
Darboe, 2001 Gambia 13.0 8.3 17.7 7.97
Pemba, 2002 South Africa 8.8 6.9 10.7 8.11
Hill, 2003 Gambia 60.6 56.4 64.8 8.00
Gill, 2003 Zambia 8.8 7.3 10.3 8.13
Blossom, 2004 Uganda 18.0 14.9 21.1 8.07
Abdullahi, 2004 Kenya 6.4 4.0 8.8 8.10
Mureithi, 2009 Gambia 80.0 66.1 93.9 6.83
Kandakai-Olukemi, 2009 Nigeria 42.0 31.7 52.3 7.36
Darboe, 2010 Gambia 78.0 72.2 83.8 7.88
Overall prevalence 28.0 19.0 37.0 100.00
I2(%), pvalue 99.00, ,0.001
(A) Children ,5years, n = 15,879 (B) Children 5–15 years, n = 7,180 (C) Adults .15 years n = 5,350.
doi:10.1371/journal.pone.0085001.t002
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common type of swab 26 (45.6%). Other types used were cotton
7(12.3%), Dacron 3(5.3%), Rayon 4(7.0%), BBL 1(1.8%) and wire
3(5.3%). Thirteen studies (22.8%) did not report the type of swab
that was used.
The majority of the studies (75.4%) were conducted in children,
11(19.3%) involved both children and adults and only 3(5.3%)
studies exclusively recruited adults. Most studies (53.0%) were in
healthy individuals, 14.0% had both healthy and sick patients,
24.5% were conducted in outpatients, 6.9% in HIV positive
populations and in 1.7% the population was not stated. In
15(26.3%) studies, participants were swabbed more than once.
Pneumococcal carriage by age and geographic region
Carriage was highest for children less than 5 years and
decreased with age (Table 2 and Figures S1, S2 & S3). High
prevalence (.85%) in children were recorded in Ethiopia,
Mozambique (only one study) and The Gambia. The Gambia
also had the highest prevalence in adults (Table 2). The prevalence
of carriage varied considerably between studies. The I2 index,
which assesses heterogeneity between studies, was greater than
99% in all the age categories. In children less than 5 years the
prevalence was higher in studies conducted in a rural, rather than
urban setting. Carriage was not associated with season, population
health, swab type or year (Table 3).
Pneumococcal carriage and gender
Eleven studies reported the prevalence of carriage by gender.
Three of these studies reported no association, one study reported
a higher prevalence in males compared to females (p = 0.05), and
one study reported a higher prevalence in females (OR=0.61;
95% CI: 0.39–0.95; p = 0.02). From our analysis, there was no
significant difference in the risk of carriage between males and
females in any of the remaining six studies (Table 4).
Table 3. Differences in the prevalence of pneumococcal carriage in sub Saharan Africa.
Prevalence (95%CI)
N+ Children ,5 years pvalue N Children 5–15 years pvalue N Adults .15 years pvalue
Region
East 8 64.5(43.5–85.5) 0.73 4 42.5(24.2–89.2) 0.72 2 12.2(261.5–85.9) 0.06
Central 1 71.2 6 36.1(19.6–52.6) 0 -
Southern 15 56.4(44.8–67.9) 0 - 5 9.3(7.8–10.9)
West 15 68.8(55.3–82.) 3 54.9(235.0–144.8) 6 49.3(19.2–79.3)
Settlement
Rural 16 80.2(70.5–89.9) ,0.0001 5 55.7(16.1–95.3) 0.26 6 32.9(1.8–63.9) 0.44
Urban 15 53.4(45.2–61.7) 5 35.3(13.4–57.2) 4 19.5(23.7–42.7)
Season
Dry 13 64.7(54.8–74.6) 0.54 5 31.4(11.4–51.3) na 3 9.6(6.6–12.6) na
Rainy 6 58.4(31.1–85.9) 0 - 0 -
Populationa
Well 21 69.2(59.5–78.9) 0.11 8 44.3(19.1–69.5) 0.97 9 36.1(13.1–59.1) 0.33
Sickb 10 64.3(50.2–78.4) 3 35.5(21.7–72.7) 0 -
HIV 1 22.2 1 55.0 2 13.3(245.1–71.7)
Yearc
Before 2000 19 63.7(54.4–72.9) 0.92 5 34.9(12.4–57.3) 0.39 4 10.8(7.7–13.8) 0.22
After 2000 20 62.8(50.4–75.3) 8 47.5(24.3–70.8) 9 34.8(11.2–58.3)
Swab route
NPS 37 64.6(57.1–72.2) na 11 48.1(32.8–63.3) 0.06 11 31.2(11.9–50.5) 0.67
OPS 0 - 2 13.3(220.2–46.1) 1 18.0
Swab type
WHOd 21 60.9(50.5–71.3) 6 45.5(22.1–68.9) 6 22.3(26.4–51.0)
Others 10 59.9(44.1–75.8) 0.91 5 36.9. (8.1–65.8) 0.55 6 26.3(3.84–48.9) 0.78
na- not applicable,
aexcluded studies with both sick and well when prevalence was not available by category.
ball illnesses including pneumonia & upper respiratory tract infections.
cPCV first licensed 2000,
dWHO recommended calcium alginate & Dacro; p-values and prevalences based on meta-regression; N+=no. of studies;
Data were used from N= 55 studies. Three studies contributed data to all three age groups, five studies contributed to ,5 yrs and .15 yrs, 31 studies contributed to
,5 yrs only, 10 studies contributed to 5–15 yrs only, and five studies contributed to .15 yrs only. Settlement, season, population, swab route and swab type were not
recorded in all studies, and for these variables we have used studies where data were available.
doi:10.1371/journal.pone.0085001.t003
Pneumococcal Carriage in Sub Saharan Africa
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e85001
PCV and pneumococcal carriage
Seven studies from three countries (The Gambia, Kenya and
South Africa) assessed the association between PCV and carriage.
One study from the Gambia was a village cluster randomised trial
with adults and older children in 10 villages receiving one dose of
PCV 7, and adults and older children in 11 control villages
receiving meningococcal serogroup C vaccine. In both arms of the
trial, infants aged between 2 and 11 months received three doses of
the vaccine given at monthly intervals, and children aged between
12 and 30 months received two doses at one month interval
between doses. Infants born during the study received three doses
of the vaccine given monthly at the ages 2, 3, and 4 months [24].
The other six studies compared carriage in vaccinated and
unvaccinated children using data from individually randomised
control trials (RCTs). Four of these studies collected carriage data
on all children that participated in the trial [25–28] while two
studies used data from a subsample of children enrolled in the
original trial [29,30] (Table 5).
The participants in all the PCV studies were children from the
general population presenting at infant welfare clinics for
immunisation, except for the village cluster randomized trial
which recruited children and adults in the community. Carriage of
vaccine type (VT) serotypes was reduced by vaccination, while
carriage of non-vaccine type serotypes was greater among
vaccinated children (Figure 2 & Table 5). The prevalence of
overall carriage was not affected by vaccination.
Pneumococcal carriage serotypes in Africa
Twenty eight (49.1%) of the studies had collected data on
serotypes and in total 6904 isolates were serotyped in these studies.
The seven studies with PCV intervention were excluded from this
analysis. There were 70 serotypes and serogroups. Serotype 19F
was among the five most prevalent serotypes in 14/21 studies,
serotype 6B in 13/21, serotype 14 in 13/21, serotype 6A in 11/21
and serotype 23F in 9/21 studies. Some studies only described
serogroups, and in these studies serogroups 19 and 6 were the most
common. In the PCV 9 vaccine trial in South Africa, serotypes 6B,
19F and 23F were the most common vaccine serotypes in both
vaccinated (6B 3.3%, 19F 7.8%, 23F 2.9%) and control (6B
11.7%, 19F 13.4%, 23F 5.8%) groups, and serotype 6B and 19F
were significantly less frequent in the PCV 9 vaccinated children.
15 (9.1%), 6A (5.8%) and 19A (2.9%) were the most common
NVT serotypes/serogroup in the vaccinees, with serogroup 15
significantly increased in vaccinated compared to control children
(9.1% versus 3.8%, p value 0.017) [28].
In The Gambia, the carriage study during the PCV 9 trial found
that serotype 19F (11.5%) was again the most common VT
serotype isolated and serogroup 15 was the most common NVT,
and more prevalent in the PCV 9 vaccinated children (11.8%
versus 8.5%, P,0.05). When the study children were swabbed a
second time about 10 months later, NVT serotypes 10, 21 and
35B were isolated more frequently from PCV 9 vaccinated
children than controls. There was no longer any difference
between the groups for carriage of serotype 19F [29]. In the cluster
randomised trial conducted in The Gambia, serotypes 23F, 6A,
6B, 3, 11 and 7C were the most common serotypes before
vaccination and serotypes 3, 11, 19F and 6A were the most
common serotypes after vaccination [24].
Discussion
This systematic review of pneumococcal carriage in sSA
summarises the prevalence of carriage, distribution of serotypes
and the effect of PCV on carriage. The majority of the studies
were from Southern and West Africa, particularly South Africa
and the Gambia. There were only two studies from Central Africa.
We found that the prevalence of pneumococcal carriage in sSA
is generally high but there is much variation between countries,
particularly among older age groups. Carriage was higher in
children than adults as reported outside sSA [31,32].
A small number of studies conducted outside sSA have reported
a higher prevalence of carriage in males compared to females [33–
35]. However, in this review gender was not associated with
Table 4. Prevalence of pneumococcal carriage in Africa by gender.
Country Ref Age grp Prevalence % (n/N) RD 95%CI Pvalue
Male Female
Uganda [51] Children 62.3 (66/106) 61.2(52/85) 0.01 20.13,0.15 0.88
Uganda [55] Adults 25.9(28/108) 18.3(80/438) 0.08 20.01,0.17 0.08
South Africaa [36] Children ns ns - 0.02
South Africab [45] Adults 8.8(75/854) 0.0(0/2) 0.09 na 1.00
Ghana [79] Infants 47.5 (75/158) 49.7(76/153) 20.02 20.13, 0.09 0.73
Nigeria [37] Children (ns/55) (ns/45) - - 0.05
Zambia [64] Children 70.9 (93/131) 71.9(92/128) 20.01 20.12,0.10 0.88
Kenyaa [6] All ages ns ns - - nd
Kenya [54] Children 32.3(11/34) 39.5(17/43) 20.07 20.29,0.14 0.64
Gambia [83] All ages ns ns - nd
Malawi [66] Children 48.9(ns) 46.3(ns) 0.03 - nd
RD- Risk difference, ns- not stated, nd-no difference reported in paper, na – not applicable, Ref-reference,
aOR = 0.61 (95% CI: 0.39, 0.95),
bHIV infected mineworkers 99.8% male, p-value based on Fisher’s exact test.
doi:10.1371/journal.pone.0085001.t004
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Table 5. Studies of pneumococcal conjugate vaccination and carriage in Africa (n = 9,549).
Trial arm n/N (%)
1st Author Year Country
Valency,
Study
design
Age PCV
administered
(w/m/y)
Age
swabbed
(w/m/y) Serotypes PCVb+c RD pvalue
SK Obaro 1995 Gambia PCV 5 2, 3,4 w PCV3+1 Control
PPV 18 m
RCTa 24 m Overall 22/26(84.6) 150/160(93.8) 20.09 0.112
VT 13/26(50.0) 144/160(90.0) 20.40 ,0.001
NVT 20/26(76.9) 68/160(42.5) 0.34 0.001
N.Mbelle 1999 S. Africa PCV 9 6, 10,14 w PCV3 Control
RCT 6 w Overall 64/250(25.6) 74/250(29.6) 20.04 0.368
10 w Overall 110/249(44.2) 109/249(43.8) 0.004 1.000
14 w Overall 115/246(46.7) 127/247(51.4) 20.05 0.322
9 m Overall 130/242(53.7) 145/239(60.7) 20.07 0.140
VTd 43/242(17.8) 86/239(36.0) 20.18 ,0.001
NVT 87/242(36.0) 59/239(24.7) 0.11 0.008
SK Obaro 2000 Gambia PCV 9 2, 3, 4 m PCV3 Control
RCT 5 m Overall 92/100(92.0) 94/102 (92.2) 20.002 1.000
VT 54/100(54.0) 64/102 (62.7) 20.09 0.253
NVT 45/100 (45.0) 33/102 (32.4) 0.13 0.083
9 m Overall 83/98 (84.7) 87/99(87.9) 20.03 0.541
VT 61/98(62.2) 74/99(74.7) 20.13 0.067
NVT 28/98(28.6) 16/99(16.2) 0.12 0.041
YB.Cheung 2003 Gambia PCV 9 2, 3, 4 m PCV3 Control
nested 9–15 m Overall 943/1078(87.5) 914/1061(86.1) 0.01 0.371
Cohort, VT 237/1051(22.5) 416/1041(40.0) 20.17 ,0.001
RCT NVT 449/1051(42.7) 280/1041(26.9) 0.16 ,0.001
21–27 m Overall 793/967(82.0) 813/961(84.6) 20.03 0.143
VT 230/922(24.9) 381/925(41.2) 20.16 ,0.001
NVT 373/922(40.5) 242/925(26.2) 0.14 ,0.001
J. A Scott* 2004/7 Kenya PCV 7 0 or 6 & 10, 14 w PCV3+1e PCV3+1f
PCV7/PPV 36 w 18 w Overallg 205/263(78.0) -
RCT VT ns(25.0) ns(31.0) 20.06 0.280
36 w Overallg 188/244(77.0) -
NVT ns(62.0) ns(51.0) 0.11 0.250
M.Ota* 2011 Gambia PCV 7 2, 3, 4 m PCV3+1 PCV1+1
PPV 10 m 5 m Overall 177/215(82.3) 178/217(82.0) 0.003 1.000
RCT VT 29/215(13.5) 43/217(19.8) 20.06 0.093
NVT 151/215(70.2) 138/217(63.6) 0.07 0.153
11 m Overall 143/200(71.5) 155/203(76.4) 20.05 0.307
VT 20/200(10.0) 41/203(20.2) 20.10 0.005
NVT 123/200(61.5) 117/203(57.6) 0.04 0.478
15 m Overall 159/194(82.0) 181/205(88.3) 20.06 0.090
VT 24/194(12.4) 38/205(18.5) 20.06 0.098
NVT 136/194(70.1) 149/205(72.7) 20.03 0.581
A.Roca* 2003/8 Gambia PCV 7 All ages PCV1 Control
clustered 2–5 yh Overall 79/90(87.8) 53/59(89.8) 20.02 0.796
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carriage in 9/11 studies, and in two studies carriage was more
common among females [36,37]. One of these studies was
conducted in South Africa among children 1–59 months with
severe pneumonia, 67.3% of whom were HIV positive and
another was in Nigeria in children 1–4 years who presented for
regular check-up or immunisation, some of whom had a cough
and a cold.
The five serotypes that were most common in this review are
among the seven that cause most global IPD in children; PCV 10
and PCV 13 will cover at least 70% of the cases of IPD caused by
these serotypes [38,39]. The other two serotypes, serotypes 1 and
5, are rarely isolated from carriage studies, although they are often
associated with pneumococcal disease epidemics [40–42]. Sero-
types also differ in their ability to cause invasive pneumococcal
disease [43].
It has been suggested that the impact of PCV on disease can be
determined by pneumococcal carriage studies because it is newly
acquired serotypes that lead to disease [9]. In this review, studies
that assessed the impact of PCV on carriage generally showed a
decrease in carriage of VT and an increase in NVT serotypes, with
no change in the overall prevalence of carriage. One study in this
review, and one in native Indians have shown a gradual decrease
in overall carriage following vaccination [24,35]. Continuous
surveillance of circulating serotypes will be important as countries
introduce PCV.
Nasopharyngeal swabs are more sensitive for S.pneumoniae than
the oral swabs [44,45]. The prevalence of carriage is therefore
likely to be underestimated in the four studies that used oral swabs.
The different lab methods used might also have been responsible
for some of the variability in the prevalence of carriage reported in
this review. WHO recommends calcium alginate or Dacron
polyester swabs since cotton swabs suppress the pneumococcus
[23]. However, only half of the studies (50.9%) followed the WHO
guidelines, and in 13 (22.4%) the type of swab was not stated.
Another source of variation between studies is the prevalence of
antibiotic use, since antibiotics might reduce carriage [46]. Some
studies excluded those individuals who had taken antibiotics from
their analysis. However, even when these individuals were
excluded, often different periods were used to define prior use.
We have combined results from all available published studies
irrespective of the study population (unpublished studies were not
included in this review). Study participants were recruited from the
community, day care centres, schools and outpatient clinics and
hospital wards. Hospital patients may have higher carriage than
the rest of the population, particularly if they were admitted for
pneumonia. Generally, we expect selection bias to be less in studies
conducted in the community compared with studies that use
outpatient clinics. In this review, 57.9% of the studies were
conducted in hospital/clinic settings and 35.1% of the studies in
the community.
We have summarised available data on pneumococcal carriage
in sub Saharan Africa. There remain unexplained differences in
carriage within the region, and multi centre studies may provide
reasons for some of the differences seen. Pneumococcal carriage
studies can show indirect effects of PCV by showing changes in
unvaccinated age groups and can supplement disease surveillance
studies as PCV is introduced in the region.
Table 5. Cont.
Trial arm n/N (%)
1st Author Year Country
Valency,
Study
design
Age PCV
administered
(w/m/y)
Age
swabbed
(w/m/y) Serotypes PCVb+c RD pvalue
RCT VT 18/90(20.0) 17/59(28.8) 20.09 0.239
NVT 61/90(67.6) 39/59(66.1) 0.02 0.860
2–5 yi Overall 23/30(76.7) 30/38(78.9) 20.02 1.000
VT 4/30(13.3) 9/38(23.7) 20.10 0.360
NVT 19/30(63. 6) 23/38(60.5) 0.03 1.000
w-weeks, m-months, y-years, RD- Risk difference- Risk in the PCV vaccinated group minus the risk in the control group calculated in Stata, PPV-Polyvalent polysaccharide
vaccine, ns- not stated,
achildren who received PCV 5 in an RCT and controls matched with age and place of residence who did not receive PCV, PCVb+c received b+c doses of PCV doses with
bfor the primary series and
cfor booster dose,
dincludes vaccine associated serotypes.
ereceived PCV7 at 6, 10 and 14 weeks,
freceived PCV7 at 6, 10 and 14 weeks or at 0, 10 and 14 weeks,
gOverall carriage for both groups,
h4–6 months after vaccination,
i22 months after vaccination;
*these three studies were not included in the meta-analysis (in these 3 studies, both groups received PCV).P-value obtained using Fisher’s exact test.
doi:10.1371/journal.pone.0085001.t005
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Figure S1 Pneumococcal carriage in children ,5 years.
(Forest plot).
(TIF)
Figure S2 Pneumococcal carriage in children 5–15
years. (Forest plot).
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Figure S3 Pneumococcal carriage in adults .15 years.
(Forest plot).
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Figure 2. A comparison of pneumococcal carriage in vaccinated and unvaccinated children aged 9–24 months. A positive risk
difference indicates higher prevalence in the vaccinated arm.
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